Ga Syfovre denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for ga syfovre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Syfovre as Experimental — and How to Appeal

Syfovre (pegcetacoplan) received FDA approval for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Despite that approval, Aetna may issue an "experimental or investigational" denial if its internal Clinical Policy Bulletin has not yet been updated to reflect the current FDA label, if the plan's coverage determination lags the approval date, or if a specific patient presentation falls outside criteria Aetna has designated as covered. These denials are particularly egregious when the drug carries a valid FDA approval and are frequently overturned.

## Why This Denial Is Appealable

Federal and state law distinguish between treatments that are genuinely experimental and those that are FDA-approved for the exact indication being treated. An insurer cannot categorically call an FDA-approved drug "experimental" for its approved indication and prevail at external review. The clinical record and the FDA approval itself are typically sufficient to overturn this type of denial.

## Federal Appeal Rights

• ACA §2719 / ERISA §503: You are entitled to a full-and-fair review. External review organizations are specifically empowered to overturn experimental-or-investigational denials when the treatment is supported by the FDA approval or applicable clinical guidelines.
• External Review: The Independent Review Organization (IRO) reviewing this case can — and frequently does — reverse experimental denials for FDA-approved drugs. The standard external review window is approximately four months from the final internal denial. Expedited review is available when delay threatens vision or health.
• State Protections: Many states have enacted laws requiring coverage of FDA-approved treatments and prohibiting experimental designations for on-label uses.

## Appeal Timeline

1. Obtain the denial letter and the specific Aetna Clinical Policy Bulletin cited. 2. Compare the policy's "experimental" designation against the current FDA approval status and label. 3. Submit the internal appeal with the FDA label, prescriber letter, and the specific GA diagnosis documentation. 4. If denied internally, proceed immediately to external review — these cases have a high IRO reversal rate.

## Documentation to Gather

• FDA approval documentation: A copy of the current FDA-approved prescribing information for Syfovre confirming the approved indication.
• Diagnosis confirmation: Retinal imaging confirming geographic atrophy secondary to AMD, with lesion characteristics documented.
• Prescriber medical-necessity letter: Your retina specialist should attest that this is an on-label use, reference the FDA approval, and cite the applicable professional society guideline (e.g., American Academy of Ophthalmology) by organization name for support of appropriate use.
• Clinical severity documentation: Documentation of GA lesion size, proximity to fixation, and rate of progression justifying treatment initiation.

## Criteria-Mapping Strategy

Obtain the most recent version of Aetna's Clinical Policy Bulletin for this drug. Identify whether the "experimental" classification is blanket (applied to the entire class) or criterion-specific. If blanket, the FDA label alone may be dispositive. If criterion-specific, list each criterion and map your chart facts to it. Ensure the prescriber letter explicitly states the on-label nature of the use and references the FDA-approved indication language directly. Your IRO reviewer will compare the FDA label against Aetna's policy — make that comparison easy.